The investigators showed that single inhibition of JAK1 or JAK2 was not as effective as the double blockade with Ruxolitinib, hypothesizing that balanced blockade of both kinases is needed to optimally control GvHD. The gene discussed is JAK2; the disease is graft versus host disease.